Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
Got $3,000? These 3 Stocks Are Screaming Buys During the Market Sell-Off
05:21am, Thursday, 12'th May 2022
You don't need a mountain of money to build wealth on Wall Street.
Is Vertex Pharmaceuticals' Billion-Dollar Business Getting Even Bigger?
06:00am, Monday, 09'th May 2022
The company may extend its leadership in cystic fibrosis treatment.
One Biotech Stock to Hold; Another to Dump Right Now
11:30am, Saturday, 07'th May 2022
Biotech stocks have been successful in going public without revenues because the story of a pharmaceutical firm gaining FDA approval for a new drug is attractive to many investors.
Vertex: Q1 Results Solid, If Unspectacular, But Pipeline Progress Makes Bull Case
07:23pm, Friday, 06'th May 2022
Vertex announced Q122 results yesterday, reporting revenues of $2.1bn and guiding for FY revenues of ~$8.5bn. Net profit margin was ~17%, while operating margin is >50% - highly impressive.
Vertex (VRTX) Q1 Earnings Lag, Sales Top, Expense View Tweaked
12:02pm, Friday, 06'th May 2022
Vertex Pharmaceuticals' (VRTX) earnings miss estimates while sales beat the same for the first quarter of 2022. The company maintains its revenue guidance for 2022.
Vertex Pharmaceuticals Incorporated (VRTX) CEO Dr. Reshma Kewalramani on Q1 2022 Results - Earnings Call Transcript
09:05pm, Thursday, 05'th May 2022
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Michael Partridge - SVP of IR Reshma Kewalramani - CEO, President and Di
Vertex Pharmaceuticals (VRTX) Q1 Earnings Miss Estimates
06:49pm, Thursday, 05'th May 2022
Vertex (VRTX) delivered earnings and revenue surprises of -2.22% and 0.79%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Parnassus Comments on Vertex Pharmaceuticals
05:04pm, Thursday, 05'th May 2022
Our biggest winner was Vertex Pharmaceuticals ( VRTX , Financial). It contributed 0.44% to the Fund's relative return, as its stock soared 18.8%.
FATE's Loss Narrower Than Expected in Q1, Pipeline in Focus
12:03pm, Thursday, 05'th May 2022
FATE reports a narrower loss and higher collaboration revenues in the first quarter.
This Stock Is Trouncing the Market in 2022 -- and Its Prospects Just Got Even Better
05:52am, Thursday, 05'th May 2022
The big biotech's winning ways are likely to continue.
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More
04:33pm, Wednesday, 04'th May 2022
Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.
5 Large-Cap Stocks to Buy Ahead of Q1 Earnings This Week
08:17am, Wednesday, 04'th May 2022
Five large-cap companies with a favorable Zacks Rank will report first-quarter earnings results this week. These are: CI, HST, BGNE, VRTX and EOG.
How Bad Is This News for Vertex Pharmaceuticals?
06:00am, Wednesday, 04'th May 2022
A potentially game-changing candidate faces a delay.
Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial Put On Hold
01:25pm, Monday, 02'nd May 2022
The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) VX-880 Phase 1/2 study due to a determination that there is insufficient information to support dose
Why Vertex Pharmaceuticals Shares Are Falling
09:25am, Monday, 02'nd May 2022
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) shares are trading lower by 3.42% to $263.88 during Monday's pre-market session after the company announced VX-880 Phase 1/2 has been placed on clini
